Can having a gastric lap band help with insulin resistance? For many people living with obesity-related metabolic conditions, this is an important question. The laparoscopic adjustable gastric band (LAGB) is a bariatric procedure that restricts food intake, promoting gradual weight loss — and weight loss is one of the most effective ways to improve insulin sensitivity. This article explores how the LAGB works, what the clinical evidence says about its impact on insulin resistance, how it compares to other bariatric procedures, and what UK patients need to know about NHS eligibility and pre-surgical considerations.

How Insulin Resistance Develops and Why Weight Plays a Role

Insulin resistance occurs when cells become less responsive to insulin, and excess visceral fat is a key modifiable driver; even 5–10% weight loss can meaningfully improve insulin sensitivity and lower HbA1c.

Insulin resistance occurs when the body's cells — particularly in the liver, muscles, and adipose tissue — become less responsive to the hormone insulin. Normally, insulin acts as a key that allows glucose to enter cells for energy. When resistance develops, the pancreas compensates by producing more insulin, leading to elevated circulating levels (hyperinsulinaemia). Over time, this can progress to type 2 diabetes if the pancreas can no longer keep pace with demand.

Excess body weight, particularly visceral (abdominal) fat, is one of the most significant modifiable risk factors for insulin resistance. Visceral adipose tissue is metabolically active and releases pro-inflammatory cytokines and free fatty acids that directly impair insulin signalling pathways. This creates a cycle in which weight gain worsens insulin resistance, and insulin resistance itself can promote further fat storage.

Not sure if this is normal? Chat with one of our pharmacists →

It is important to note that insulin resistance can occur in people without obesity. Other contributing factors include physical inactivity, increasing age, genetic predisposition, certain ethnic backgrounds (including South Asian and Black African or Caribbean heritage), polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD), obstructive sleep apnoea, and the use of certain medicines such as corticosteroids.

Obesity-related insulin resistance is also closely linked to other components of metabolic syndrome, including:

• Elevated blood pressure

• Dyslipidaemia (abnormal cholesterol and triglyceride levels)

• Increased cardiovascular risk

Even modest weight loss of 5–10% of total body weight has been shown to meaningfully improve insulin sensitivity, reduce fasting glucose, and lower HbA1c levels, as reflected in NICE guidance (NG28: Type 2 diabetes in adults: management). This is why weight management — through lifestyle changes, medication, or surgical intervention — sits at the heart of managing insulin resistance and preventing progression to type 2 diabetes.

What a Laparoscopic Adjustable Gastric Band (LAGB) Does and How It Works

LAGB is a reversible, purely restrictive bariatric procedure that creates a small stomach pouch to limit food intake; it does not alter digestive anatomy or affect nutrient absorption.

A laparoscopic adjustable gastric band (LAGB) — sometimes referred to colloquially as a gastric lap band — is a bariatric procedure in which a silicone band is placed laparoscopically around the upper portion of the stomach. This creates a small pouch above the band, significantly restricting the amount of food a person can comfortably consume at one time. The band is connected via tubing to a small port placed beneath the skin, allowing a clinician to adjust the tightness of the band by injecting or removing saline solution.

Unlike gastric bypass or sleeve gastrectomy, the LAGB does not alter the anatomy of the digestive tract or affect nutrient absorption. Its mechanism is purely restrictive — it slows the passage of food and promotes earlier satiety by stimulating stretch receptors in the stomach wall. This leads to reduced caloric intake and, over time, gradual weight loss.

The procedure is generally considered reversible, as the band can be removed laparoscopically if necessary. However, it is important to qualify this: whilst the LAGB has a lower immediate surgical risk than more complex procedures, it is associated with higher rates of long-term device-related complications and reoperation or removal compared with sleeve gastrectomy or gastric bypass. As a result, LAGB is now less commonly offered within NHS services, and availability varies by centre and Integrated Care Board (ICB).

Common side effects and complications to be aware of include:

• Nausea and vomiting, particularly if eating too quickly

• Dysphagia (difficulty swallowing)

• Gastro-oesophageal reflux and oesophagitis

• Pouch or oesophageal dilatation

• Band slippage, acute obstruction, or erosion

• Gastric perforation (rare)

• Port-site discomfort or infection

• Band intolerance requiring removal and possible revisional surgery

• Inadequate weight loss in some patients

Patients are advised to follow specific dietary guidelines post-operatively and attend regular review appointments with their bariatric team. In line with guidance from the British Obesity and Metabolic Surgery Society (BOMSS), all patients who have undergone bariatric surgery — including LAGB — should receive lifelong nutritional supplementation (typically a comprehensive multivitamin and mineral supplement) and undergo scheduled biochemical monitoring, even though the malabsorption risk with LAGB is lower than with bypass procedures.

If you experience any problems that you suspect may be related to your gastric band device, you can report these via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Evidence on LAGB and Improvements in Insulin Resistance

LAGB produces clinically meaningful improvements in insulin resistance and glycaemic control, though diabetes remission rates and long-term HbA1c reductions are more modest than those achieved with bypass or sleeve procedures.

There is a body of evidence suggesting that LAGB can lead to meaningful improvements in insulin resistance, primarily through the mechanism of sustained weight loss. Studies have demonstrated reductions in fasting insulin levels, improved insulin sensitivity indices, and lower HbA1c values following adjustable gastric banding in individuals with obesity and type 2 diabetes or pre-diabetes.

A landmark Australian randomised controlled trial (Dixon JB et al., JAMA 2008;299:316–323) found that gastric banding led to remission of type 2 diabetes in 73% of participants, compared with 13% in the conventional therapy group, over a two-year period. Improvements in insulin resistance were closely correlated with the degree of weight loss achieved. This suggests that the metabolic benefits are largely — though not exclusively — weight-dependent. It should be noted that this trial had a relatively small sample size, and findings should be interpreted alongside broader systematic review evidence.

Importantly, the durability of diabetes remission following LAGB is generally lower than that seen with Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy. Cochrane reviews and meta-analyses comparing bariatric procedures consistently show that whilst LAGB produces clinically meaningful improvements in glycaemic control, rates of complete diabetes remission and long-term HbA1c reduction are more modest than those achieved with bypass or sleeve procedures. Some patients may achieve a reduction in diabetes medication rather than full remission.

Furthermore, improvements seen with LAGB tend to be more gradual than those observed with bypass surgery. Some research indicates that bypass surgery produces early improvements in insulin sensitivity that occur before significant weight loss, suggesting additional hormonal mechanisms (such as changes in GLP-1 and ghrelin secretion) that the LAGB does not replicate.

Overall, the evidence supports LAGB as a clinically effective option for improving insulin resistance in appropriately selected patients, particularly those who achieve sustained weight loss. Outcomes are, however, highly dependent on patient adherence to dietary and lifestyle recommendations, as well as regular band adjustments and clinical follow-up.

How LAGB Outcomes Compare to Other Bariatric Procedures

Roux-en-Y gastric bypass and sleeve gastrectomy produce superior and more rapid improvements in insulin resistance than LAGB, partly due to additional hormonal mechanisms such as increased GLP-1 secretion.

When comparing bariatric procedures for their impact on insulin resistance and type 2 diabetes, LAGB generally produces less dramatic metabolic improvements than malabsorptive or combined procedures. Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy are consistently associated with greater and more rapid improvements in glycaemic control, often within days of surgery — well before significant weight loss has occurred.

This early metabolic effect in bypass surgery is thought to be driven by changes in gut hormone secretion, particularly increased GLP-1 (glucagon-like peptide-1) and reduced ghrelin, which directly enhance insulin sensitivity and beta-cell function. The LAGB, operating purely through restriction, does not trigger these hormonal changes to the same extent.

Systematic reviews and meta-analyses — including those published in The Lancet Diabetes & Endocrinology — confirm that whilst all bariatric procedures improve metabolic outcomes, RYGB and sleeve gastrectomy produce superior results for diabetes remission and weight loss maintenance over five or more years. Long-term data also show that LAGB is associated with higher rates of reoperation, device removal, and revisional surgery compared with sleeve gastrectomy or bypass. These factors have contributed to a significant decline in LAGB use within the NHS over the past decade.

That said, the LAGB remains a valid option for certain patients, particularly those who:

• Prefer a reversible procedure

• Have a lower BMI within the surgical threshold

• Have contraindications to more invasive surgery

• Wish to avoid the nutritional risks associated with malabsorptive procedures

The choice of procedure should always be made collaboratively between the patient and a specialist multidisciplinary bariatric team, taking into account individual health status, preferences, procedure availability at the treating centre, and overall risk profile. BOMSS position statements on procedure selection provide further guidance for clinical teams.

NHS Eligibility Criteria for Bariatric Surgery in the UK

NHS bariatric surgery is available to adults with a BMI ≥40 kg/m², or ≥35 kg/m² with a significant comorbidity, who have not achieved adequate weight loss through non-surgical interventions, per NICE guidelines CG189 and NG28.

In England, access to bariatric surgery on the NHS is guided by NICE Clinical Guideline CG189 (Obesity: identification, assessment and management) and NICE Guideline NG28 (Type 2 diabetes in adults: management). To be considered for bariatric surgery, patients generally need to meet the following criteria:

• BMI of 40 kg/m² or above, or

• BMI of 35–39.9 kg/m² with a significant obesity-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea

• Have tried and not achieved adequate weight loss through non-surgical interventions (such as supervised diet, exercise, and behavioural programmes)

• Be fit for anaesthesia and surgery

• Commit to long-term follow-up

NICE also recommends that adults with a BMI of 30–34.9 kg/m² who have recent-onset type 2 diabetes should be considered for assessment for bariatric surgery, particularly if other treatments have not achieved adequate glycaemic control. For adults with a BMI of 35 kg/m² or above and recent-onset type 2 diabetes, expedited assessment should be offered.

Importantly, for adults from South Asian, Chinese, and some other minority ethnic backgrounds, NICE recommends applying BMI thresholds that are approximately 2.5 kg/m² lower than the standard thresholds, in recognition of the higher metabolic risk at lower BMI in these populations.

It is worth noting that NHS provision of bariatric surgery varies across Integrated Care Boards (ICBs) in England, and waiting times can be lengthy. NHS England specialised commissioning policies and local ICB criteria should be consulted for up-to-date eligibility and referral requirements. Patients in Scotland, Wales, and Northern Ireland are subject to their respective national guidelines, which broadly align with NICE recommendations but may differ in specific thresholds or referral pathways.

Referral is typically made by a GP to a specialist tier 3 or tier 4 weight management service, where a multidisciplinary team — including dietitians, psychologists, and bariatric surgeons — will assess suitability. Private bariatric surgery is also available in the UK, though patients should ensure their provider is registered with the Care Quality Commission (CQC).

What to Discuss With Your Clinical Team Before Considering Surgery

Before LAGB, patients should discuss metabolic baseline, medication adjustments — particularly for insulin, sulphonylureas, and SGLT2 inhibitors — nutritional planning, psychological readiness, and realistic expectations for weight loss and diabetes outcomes.

Before pursuing LAGB or any bariatric procedure, a thorough and honest conversation with your GP and specialist team is essential. Surgery is not a standalone solution — it works best as part of a comprehensive, long-term approach to weight management and metabolic health.

Key topics to raise with your clinical team include:

• Your current metabolic health status — including HbA1c, fasting glucose, lipid profile, and blood pressure, to establish a baseline and assess the urgency of intervention

• Medication review — some diabetes medicines, including insulin and sulphonylureas, may need to be adjusted or discontinued after surgery to avoid hypoglycaemia. If you are taking an SGLT2 inhibitor (such as dapagliflozin, empagliflozin, or canagliflozin), this should be paused in the perioperative period due to the risk of euglycaemic diabetic ketoacidosis (DKA); your clinical team will advise when it is safe to restart, in line with UK perioperative diabetes guidance

• Nutritional considerations — whilst the LAGB carries a lower malabsorption risk than bypass procedures, dietary habits must change significantly post-operatively. In line with BOMSS guidance, lifelong vitamin and mineral supplementation and regular biochemical monitoring are recommended for all bariatric patients, including those with an LAGB; a dietitian referral is standard practice

• Psychological readiness — bariatric teams routinely assess mental health, eating behaviours, and motivation, as these significantly influence long-term outcomes

• Realistic expectations — weight loss with an LAGB is typically slower and more variable than with bypass or sleeve procedures, and complete diabetes remission is less likely; understanding this helps prevent disappointment

• Pregnancy planning — if you are of childbearing age, discuss timing of surgery and contraception; it is generally advised to defer pregnancy for at least 12–18 months after bariatric surgery, and the band may need to be deflated during pregnancy

Patients should be aware of when to seek urgent medical advice after surgery. Contact NHS 111 or attend your nearest A&E if you experience:

• Inability to swallow liquids or keep any fluids down

• Severe or worsening abdominal or chest pain

• Breathlessness

• Persistent vomiting

• Fever, rapid heart rate, or signs of infection around the port site

If you are managing insulin resistance or type 2 diabetes and are concerned about your weight, the first step is to speak with your GP, who can refer you to appropriate weight management services and help determine whether surgical intervention may be suitable for your individual circumstances.

Have questions about your medication? Our pharmacists are here to help →

Frequently Asked Questions